Rodman & Renshaw downgrades Karyopharm Therapeutics to Neutral from Buy

Rodman & Renshaw downgraded Karyopharm Therapeutics (KPTI) to Neutral and withdrew its price target after the company filed for Chapter 11 bankruptcy. Karyopharm has $328.53 million in debt and a market cap of $2.45 million, with a 89% stock decline over the past year. The company entered a restructuring agreement with lenders and noteholders, but equity holders' recovery is uncertain.

Karyopharm Therapeutics, a cancer drugmaker, filed for bankruptcy to sell itself. Ayrmid, parent of Gamida Cell, is the lead bidder. Karyopharm reported $115M in Xpovio sales, $196M in losses, and $1.8B accumulated deficit. The company aims to close the deal by early 2027, with a $55M bankruptcy loan supporting operations.

Karyopharm Therapeutics (KPTI) filed for Chapter 11 bankruptcy and agreed to a merger with Ayrmid, securing $55M in financing. The deal, expected to close in Q1 2027, is subject to court approval and may face competing bids. Karyopharm will continue operations and development during restructuring.

Karyopharm Therapeutics (KPTI) filed for Chapter 11 bankruptcy, planning to merge with Ayrmid. The deal, expected to close by Q1 2027, includes a court-supervised sale process. Karyopharm secured $55M in financing and expects existing equity to have no value.

Karyopharm Therapeutics Inc. (KPTI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future – The Company Remains Focused on Supporting Patients and Advancing its Programs in Multiple Myeloma and Myelofibrosis – – Ayrmid will Serve as Lead Bidder in C

Karyopharm Therapeutics (KPTI) announced plans to file for bankruptcy and merge with Ayrmid. The company secured up to $55M in debtor-in-possession financing from existing secured lenders, pending court approval. This development impacts KPTI's investors and traders.